Mylan CEO Heather Bresch with EpiPens.Reuters The FDA on Thursday approved Teva Pharmaceuticals’ generic version of the drug, dealing a blow to branded EpiPen-maker Mylan. Mylan saw an...
Joe Raedle/Getty ImagesIn 2016, the EpiPen became a symbol of the drug-pricing problem in the US. Over a decade, the price for a two-pack has gone...
One of Crossover Health’s exam rooms at its Midtown, Manhattan location.Courtesy Crossover Health Crossover Health, a company that runs on-site or near-site healthcare clinics for large...
Mario Schlosser, CEO and co-founder of Oscar. Eduardo Munoz/Reuters Oscar Health just raised an additional $375 million from Alphabet, bringing the health insurer’s total funding up...
One of Dr. Consulta’s clinics in Sao Paolo Courtesy Dr. Consulta Meet Dr. Consulta, a Brazil-based healthcare company that provides set prices for healthcare services like...
GV general partner Krishna Yeshwant uses a healthy amount of skepticism when vetting potential companies to invest in. His favorite time to invest is when one...
REUTERS/Brendan McDermid Billionaire investor Carl Icahn is not a fan of Cigna’s plan to purchase pharmacy benefit manager Express Scripts, a $67 billion deal that was...
Optum Enterprise Analytics Steve Griffiths and Dr. Arthur Forni speak with Business Insider via Skype.Courtesy OptumIQ Optum, the health services arm of America’s largest insurer United...
Samumed CEO Osman Kibar, CFO Cevdet Samikoglu, and chief medical officer Yusuf Yazici Diana Yukari/Business Insider; photos courtesy Samumed Samumed, a San Diego-based biotech is one...
Reuters Carl Icahn is reportedly not a fan of Cigna’s $67 billion merger with Express Scripts. Shares of the pharmacy benefits manager fell as much as 8%...